Top-15 Global Pharma Signs Multi-Year Enterprise RWEOne Platform License

Agreement covers full RWEOne platform deployment — EDC, AI validation, RWD lake, and global site network — across three therapeutic areas and all clinical phases.

FOR IMMEDIATE RELEASE

New York — June 18, 2026 — RWEOne today announced that a top-15 global biopharmaceutical company has signed a multi-year enterprise license to deploy the RWEOne platform. The agreement covers deployment across the sponsor's oncology, cardiovascular, and immunology Phase 1-4 portfolios, including RWD lake and evidence-generation capabilities.

Scope of the Enterprise Agreement

• Electronic Data Capture (EDC) with CDISC CDASH 2026-certified eCRF builder
• AI validation engine v3 (with v4 predictive SDV upgrade upon general availability)
• Governed Real-World Data lake with federated query across three regional jurisdictions
• Global investigator site network access including the new APAC 18-country expansion
• 24/7 GxP platform operations and dedicated sponsor success team

Sponsor Rationale

After a nine-month competitive evaluation, RWEOne was the only platform that could give us end-to-end standards alignment, AI validation, and a governed RWD lake — on a single contract — without stitching together four or five point solutions.

Media Contact:
RWEOne Press Office
[email protected]